Industry news

More link think? OPDP lists social media links as guidance item for 2016

Beth Snyder Bulik / FiercePharmaMarketing

The FDA's promotional police plan to address social media links for pharma again this year. Maybe. That is, the issue is on the agency's annual agenda of "new and revised draft guidances CDER is planning to publish during calendar year 2016." And the item specifically states that the FDA plans to look at the "use of links to third-party sites," according to the guidance documen

Russia ranked one of world's most innovative economies

Marchmont Innovation News

In spite of current economic challenges, Bloomberg ranks Russia one of the world’s most innovative economies.  
Russia rose two spots to overall #12 in this year’s  Bloomberg Innovation Index , which ranks the innovative capacity of the world's top-50 innovative countries. 
 

France triples size of biotech investment fund following industry criticism

Nick Paul Taylor / Fierce Biotech

The French government is planning to triple the size of its biotech investment fund after the industry balked at the initial proposal. Officials now intend to hive off €340 million ($380 million) for the fund, more than three times the amount earmarked when they first floated the idea last year.

01 February 2016

Biomarker Discovery Gets a Fix on Cancer

Cancer Kathy Liszewski / Genetic Engineering & Biotechnology News

ust as signposts provide information, direction, and guidance, so too cancer biomarkers can better reveal the complex, dynamic, and heterogeneous landscape of malignancies. Such information is critical for creating better cancer diagnostics, prognostics, and therapeutics, but the journey to find just the right biomarker is often a long and winding road.

Despite capital markets meltdown money flows into biopharma

Peter Winter / BioWorld

With the 34th annual J.P. Morgan Healthcare conference now in our rearview mirror we can reflect on the lessons learned from that pivotal event that traditionally helps set the agenda for the industry. There is no doubt that biopharma executives attending the meeting generally believe that 2016 will be vibrant – a sentiment echoed by many of the presenting companies who indicated they were looking forward to an "exciting" year ahead. Investors seem to be of the same mind, with more than $2 billion flowing to public and private companies so far in January despite the unfavorable capital markets.

The top 10 (possible) blockbusters that (might) launch this year

John Carroll / FierceBiotech

EvaluatePharma gathered the consensus numbers on projected 2020 sales for the drugs being watched for a 2016 launch and came up with separate tallies on the top 10 biologics and top 10 small molecules. We mashed them together and came up with a top 10 for the new therapies up for a make-or-break kickoff.

These Are the World's Most Innovative Economies

Michelle Jamrisko / Bloomberg Business

In the world of ideas, South Korea is king. Germany, Sweden, Japan and Switzerland rounded out the top five in the 2016 Bloomberg Innovation Index, which scored economies using factors including research and development spending and concentration of high-tech public companies. Russia is on the 12-th place.

Siberian researchers use power of patient’s immune system to treat cancer

Marchmont Innovation News

A Novosibirsk-based innovative company called “Dendritic Cell Lab” is developing a method of fighting cancer by employing a patient’s own immune system potential, the Russian news agency TASS  reported , citing Andrei Kalichkin who runs the Siberian company. 

Cancer drug target visualized at atomic resolution

U.S. National Institute of Health

A new study shows that it is possible to use an imaging technique called cryo-electron microscopy (cryo-EM) to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells. The cryo-EM images also helped the researchers establish, at atomic resolution, the sequence of structural changes that normally occur in the protein, p97, an enzyme critical for protein regulation that is thought to be a novel anti-cancer target.

Ebola Lessons learned? Global organizations speed Zika R&D

Nuala Moran / BioWorld

Forces are starting to be marshaled against the Zika virus, with researchers calling for the experience of the Ebola crisis to be applied in expediting clinical trials of potential treatments and diagnostic tests for the newly rampant virus.